Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-(2-carboxyethyl)phenyl-trans-4-aminomethylcyclohexane Carboxylate Hydrochloride
2. Cetraxate
3. Cetraxate Hydrochloride, (trans)-isomer
4. Dv 1006
1. 27724-96-5
2. Cetraxate, Hydrochloride
3. Cetraxate Hcl
4. Neuer
5. Dv-1006
6. Cetraxate (hydrochloride)
7. Dv1006
8. Dv 1006
9. 08it6p8vhy
10. 4'-(2-carboxyethyl)phenyl-trans-4-aminomethylcyclohexane Carboxylate Hydrochloride
11. Benzenepropanoic Acid, 4-(((4-(aminomethyl)cyclohexyl)carbonyl)oxy)-, Hydrochloride, Trans-
12. P-hydroxyhydrocinnamic Acid Trans-4-(aminomethyl)cyclohexanecarboxylate, Hydrochloride
13. 27724-96-5 (hcl)
14. Dsstox_cid_26459
15. Dsstox_rid_81633
16. Dsstox_gsid_46459
17. Mls001401399
18. Cetraxato Clorhidrato
19. Cas-27724-96-5
20. Cetraxato Clorhidrato [spanish]
21. Ncgc00164584-01
22. Cetraxate Hydrochloride [usan:jan]
23. Smr000469197
24. Unii-08it6p8vhy
25. Cetraxatehydrochloride
26. Neuer (tn)
27. 3-[4-[4-(aminomethyl)cyclohexanecarbonyl]oxyphenyl]propanoic Acid;hydrochloride
28. Schembl144285
29. Schembl144286
30. Chembl502896
31. Cetraxate Hydrochloridedv 1006
32. Dtxsid3046459
33. Phenyl)propanoic Acid Hydrochloride
34. Cetraxate Hydrochloride [mi]
35. Tox21_112210
36. Cetraxate Hydrochloride [jan]
37. Mfcd01722166
38. Cetraxate Hydrochloride [usan]
39. Akos025311449
40. Akos030239788
41. Cetraxate Hydrochloride (jp17/usan)
42. Tox21_112210_1
43. Ccg-100854
44. Cetraxate Hydrochloride [mart.]
45. Nc00104
46. Cetraxate Hydrochloride [who-dd]
47. Hydrocinnamic Acid, P-hydroxy-, 4-(aminomethyl)cyclohexanecarboxylate Hydrochloride, Trans-
48. Ncgc00164584-03
49. As-58253
50. Db-047265
51. Hy-122762
52. C3454
53. Cs-0088850
54. Ft-0602999
55. D02266
56. T70707
57. A819170
58. J-016867
59. Q27236401
60. 3-(4-((1r,4r)-4-(aminomethyl)cyclohexanecarbonyloxy)
61. 3-(4-((1r,4r)-4-(aminomethyl)cyclohexanecarbonyloxy)phenyl)propanoic Acid
62. 3-[4-[[4-(aminomethyl)cyclohexyl]-oxomethoxy]phenyl]propanoic Acid Hydrochloride
63. 3-[4-[[trans-4-(aminomethyl)cyclohexyl]carbonyloxy]phenyl]propanoic Acid Hydrochloride
64. 3-{4-[4-(aminomethyl)cyclohexanecarbonyloxy]phenyl}propanoic Acid Hydrochloride
| Molecular Weight | 341.8 g/mol |
|---|---|
| Molecular Formula | C17H24ClNO4 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 7 |
| Exact Mass | 341.1393859 g/mol |
| Monoisotopic Mass | 341.1393859 g/mol |
| Topological Polar Surface Area | 89.6 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 369 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Cetraxate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cetraxate, including repackagers and relabelers. The FDA regulates Cetraxate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cetraxate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Cetraxate supplier is an individual or a company that provides Cetraxate active pharmaceutical ingredient (API) or Cetraxate finished formulations upon request. The Cetraxate suppliers may include Cetraxate API manufacturers, exporters, distributors and traders.
click here to find a list of Cetraxate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cetraxate DMF (Drug Master File) is a document detailing the whole manufacturing process of Cetraxate active pharmaceutical ingredient (API) in detail. Different forms of Cetraxate DMFs exist exist since differing nations have different regulations, such as Cetraxate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cetraxate DMF submitted to regulatory agencies in the US is known as a USDMF. Cetraxate USDMF includes data on Cetraxate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cetraxate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cetraxate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cetraxate Drug Master File in Japan (Cetraxate JDMF) empowers Cetraxate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cetraxate JDMF during the approval evaluation for pharmaceutical products. At the time of Cetraxate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cetraxate suppliers with JDMF on PharmaCompass.
Cetraxate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cetraxate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cetraxate GMP manufacturer or Cetraxate GMP API supplier for your needs.
A Cetraxate CoA (Certificate of Analysis) is a formal document that attests to Cetraxate's compliance with Cetraxate specifications and serves as a tool for batch-level quality control.
Cetraxate CoA mostly includes findings from lab analyses of a specific batch. For each Cetraxate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cetraxate may be tested according to a variety of international standards, such as European Pharmacopoeia (Cetraxate EP), Cetraxate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cetraxate USP).
LOOKING FOR A SUPPLIER?
